Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 11—November 2016
Letter

Recent Chikungunya Virus Infection in 2 Travelers Returning from Mogadishu, Somalia, to Italy, 2016

Lorenzo Zammarchi, Claudia Fortuna, Giulietta Venturi, Francesca Rinaldi, Teresa Capobianco, Maria Elena Remoli, Gian Maria Rossolini, Giovanni Rezza, and Alessandro BartoloniComments to Author 
Author affiliations: Università Degli Studi di Firenze, Florence, Italy (L. Zammarchi, F. Rinaldi, G.M. Rossolini, A. Bartoloni); Azienda Ospedaliero-Universitaria Careggi, Florence (L. Zammarchi, T. Capobianco, G.M. Rossolini, A. Bartoloni); Istituto Superiore di Sanità, Rome, Italy (C. Fortuna, G. Venturi, M.E. Remoli, G. Rezza); Università di Siena, Siena, Italy (G.M. Rossolini); Fondazione IRCCS Don Carlo Gnocchi, Florence (G.M. Rossolini)

Main Article

Table

Results of chikungunya virus testing for 2 persons who returned to Italy after traveling to Mogadishu, Somalia, 2016*

Laboratory test performed Place where test was performed Results
Patient 1† Patient 2‡
OnSite Chikungunya IgM Combo Rapid Test-Cassette (CTK Biotech, San Diego CA, USA)§
 Careggi University Hospital
 Positive
 Negative
Chikungunya virus IFA IgG (Euroimmun AG, Luebeck, Germany)¶
 Careggi University Hospital
 Titer >1:100#
 Titer >1:100#
Chikungunya virus IFA IgM (Euroimmun)**
 Careggi University Hospital
 Positive
 Positive
Anti-CHIKV IgM ELISA (Euroimmun)††
 ISS, National Reference Laboratory for Arboviruses
 Index 7.9‡‡
 Index 3.4‡‡
PRNT for Chikungunya virus ISS, National Reference Laboratory for Arboviruses PRNT80 >1:10§§ PRNT80 >1:10§§

*Testing was conducted on samples taken the day patients 1 and 2 sought care at the Infectious and Tropical Diseases Outpatient Unit at Careggi University Hospital in Florence, Italy. IFA, immunofluorescence assay; ISS, National Institute of Health in Rome, Italy; PRNT, plaque reduction neutralization test; PRNT80, 80% PRNT.
†Samples were obtained 33 d after symptom onset.
‡Samples were obtained 52 d after symptom onset.
§Sensitivity/specificity 90.3%/100% according to information reported in the kit data sheet (reference 10 in Technical Appendix, and 30%/73% according to an independent evaluation (reference 11 in Technical Appendix).
¶Sensitivity/specificity 100%/96% according to information reported in the kit data sheet (reference 12 in Technical Appendix).
#Cut-off for positivity >1:10.
**Sensitivity/specificity 95%/96% according to information reported in the kit data sheet (reference 12 in Technical Appendix).
††Sensitivity/specificity 98.1%/98.9% according to information reported in the kit data sheet (reference 13 in Technical Appendix) and 85%/82% according to an independent evaluation (reference 11 in Technical Appendix).
‡‡Cut-off for positivity >1.1.
§§PRNT80 titers >1:10 are considered positive.

Main Article

Page created: October 19, 2016
Page updated: October 19, 2016
Page reviewed: October 19, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external